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Abstract
A new live cell-based assay platform has been developed for the determination of complement dependent cytotoxicity
(CDC), antibody dependent cellular cytotoxicity (ADCC), and overall cytotoxicity in human whole blood. In these assays, the
targeted tumor cell populations are first labeled with fluorescent Cell Tracker dyes and immobilized using a DNA-based
adhesion technique. This allows the facile generation of live cell arrays that are arranged arbitrarily or in ordered rectilinear
patterns. Following the addition of antibodies in combination with serum, PBMCs, or whole blood, cell death within the
targeted population can be assessed by the addition of propidium iodide (PI) as a viability probe. The array is then analyzed
with an automated microscopic imager. The extent of cytotoxicity can be quantified accurately by comparing the number of
surviving target cells to the number of dead cells labeled with both Cell Tracker and PI. Excellent batch-to-batch
reproducibility has been achieved using this method. In addition to allowing cytotoxicity analysis to be conducted in real
time on a single cell basis, this new assay overcomes the need for hazardous radiochemicals. Fluorescently-labeled
antibodies can be used to identify individual cells that bear the targeted receptors, but yet resist the CDC and ADCC
mechanisms. This new approach also allows the use of whole blood in cytotoxicity assays, providing an assessment of
antibody efficacy in a highly relevant biological mixture. Given the rapid development of new antibody-based therapeutic
agents, this convenient assay platform is well-poised to streamline the drug discovery process significantly.
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Introduction
Antibodies are able to recognize and destroy targeted cells, such
as those corresponding to tumors or viral infections, through
complement dependent cytotoxicity (CDC) and antibody depen-
dent cellular cytotoxicity (ADCC) [1,2]. These pathways are
believed to be involved in the mechanism of action for many
antibody-based therapeutics, and thus it is imperative to be able to
assess the ability of an immunoglobulin drug candidate to elicit
these responses. Cell lysis by the CDC or ADCC process is
typically measured for a bulk population by monitoring the release
of chromium-51 (51Cr) [3] that had been previously taken up by
the cells, or by the release of lactic acid dehydrogenase (LDH)
[4,5]. The measurement of cell viability has also been successfully
measured for a CDC experiment using a soluble MTT reporter
[6,7]. Although widely used, however, all of these methods have
their shortcomings. 51Cr is radioactive, expensive, and adds
disposal difficulties, which has led to the popularity of the LDH
release method. However, this method can lead to large sample
errors in ADCC assays since both the target and effector cells
contain LDH [8,9]. All of the available methods provide an
average toxicity value for a whole population of cells, providing no
information about individual cell behavior. Finally, these tech-
niques require the evaluation of relatively large cell populations to
obtain usable reproducibility. This can be especially problematic
in cases where targeted cells are in short supply, such as the use of
blood samples from specific leukemia patients.
To address these limitations while providing increased amounts
of diagnostic information for a particular cell-treatment combina-
tion, we report herein a new cytotoxicity assay that can be used to
evaluate the response of individual cells to antibodies and other
drug candidates. The technique uses fluorescence microscopy and
automated image processing to determine the number of both
living and dead cells with a high degree of precision, and only
requires inexpensive and readily available dyes. The method can
be used in real time to provide temporal information about
cytotoxicity, and it can be used to identify cells that bear the
targeted receptor, and yet resist the CDC and ADCC mecha-
nisms. It can also clearly distinguish between targeted and effector
cells, providing accurate cytotoxicity data using the complex
samples of peripheral blood mononuclear cells (PBMCs) and even
whole blood. In this work, this analysis method is demonstrated
using leukemia and lymphoma cells and a known therapeutic
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antibody. However, the generality of the method should allow its
extension to the evaluation of many different tumor cell types and
drug candidates.
Results and Discussion
Creating Live Cell Arrays through DNA Adhesion
A key aspect of this technique is the attachment of living cells to
analysis surfaces through the use of DNA-based adhesion [10–14].
In this approach, synthetic DNA strands bearing NHS esters are
covalently conjugated to proteins on the surfaces of the target cells,
as outlined schematically Fig. 1a. Previous studies have indicated
that the modification procedure results in the addition of
,100,000 DNA strands, with no notable effects on cell morphol-
ogy or undesired pathway activation. Upon exposure to glass
surfaces bearing the sequence complements, the cells adhere
through DNA hybridization, Fig. 1b. This provides a robust
linkage that can be maintained for days if needed, while
maintaining excellent cell viability. In previous studies using
AFM, we have measured the strength of adhesion to be ,800 pN
[14]. The use of this strategy is particularly important for cells of
the immune system, as they are naturally non-adherent and thus
cannot be bound using integrin-targeting strategies. Through the
use of commercially available pre-printed platforms, large areas
with high cell densities can be prepared (Fig. 1c), as well as
ordered microarrays comprising small cell clusters (Fig. 1d). Both
96-well plate and 8-well chamber slide formats are currently
available, and can be used interchangeably in the experiments
described below. Following generation of the arrays, a brief rinse
with PBS removes any non-bound cells. In the case of the cell
microarrays, the use of this procedure provides 50006550 (11%
standard deviation for N= 5 samples) cells per well.
For experiments involving ADCC or whole blood toxicity assays
(see below), the targeted cells are also labeled with fluorescent Cell
Tracker dyes during the DNA modification step. This labeling is
not necessary for CDC assays, as no additional cells are added in
these procedures.
CDC Assays using Live Cell Arrays
To explore the use of these DNA-captured live cell populations
in the context of screening therapeutic antibody candidates,
different concentrations of a humanized anti-CD20 antibody
(produced in CHO cells, and referred to as a-CD20 herein) [15–
17] were applied to the wells of chamber slides containing arrays
of Jeko-1 lymphoma cells. Human serum (Quidel Corporation,
San Diego, CA) was then added to each well of the assay. After
4 h, the extent of CDC was determined by exposing the cells to a
solution of propidium iodide (PI). By comparing bright field and
fluorescence images, the number of living and dead cells could be
quantitated easily, Fig. 2a (also see close-up image in Fig. 3a).
Some insoluble PI stain was observed as large diffuse aggregates,
but these were easily distinguished from the cells. Triplicate
experiments indicated excellent plate-to-plate reproducibility, with
5% variability or less for all concentrations investigated, Fig. 2b.
A dose-dependent response was observed, with peak toxicity seen
at the highest a-CD20 concentration (100 mg/mL). Low levels of
cell death, ranging between 0% to 3%, were observed when Jeko-1
cells were incubated with a negative control antibody (NC Ab),
which had no affinity towards Jeko-1 cells. This result also verified
that the DNA-based adhesion method itself did not lead to losses
in cell viability. The overall results of this assay compared well to
the previously published EC50 values for other anti-CD20
antibodies (such as Rituxan), which range from 5–70 mg/mL
[18–21].
Time-lapsed Images of the CDC Process
Because this assay has the ability to track specific cells for the full
duration of the experiment, it allows one of the first real-time
explorations of the CDC process. To do this, an array of DNA-
immobilized Jeko-1 cells was exposed to a-CD20, serum, and PI
throughout the incubation process. Time-lapsed images were
acquired using an ImageXpress Micro (IXM) Automatic Imager
(Molecular Devices) and merged into a movie (see Video S1). Cell
death was observed as early as 10 min using the dose of a-CD20
(10 mg/mL), and was found to plateau after 2 h, Fig. 2c. The
ability to acquire temporal information about the CDC process is
highly useful for the evaluation of new antibody candidates, as one
experiment can provide comparative information at many
different time points. This allows for much greater efficiency in
these assays by minimizing the number of duplicate experiments
that must be run for each antibody candidate. In contrast, both the
51Cr- and the LDH-release assays are most suited for providing
data at single endpoints.
Identification of CDC Resistant Target Cells using a
Fluorescent Antibody
The ability to conduct cytotoxicity assays on an individual cell
basis provides new opportunities for the identification of drug-
resistant cells [22–25]. Live cells can be removed from the DNA-
based arrays very quickly through the addition of DNase, or
somewhat more slowly through the addition of competing
complementary DNA strands. Either technique provides live cells
that could be used for sequencing, transcriptional profiling, or
further culture.
This method is particularly informative when fluorescent
antibodies are used, as cells that lack the targeted receptor can
be distinguished from those that resist the CDC pathway through
active mechanisms. As an example, FITC-labeled a-CD20 [26]
was used to identify the receptor-positive target cells. After
incubation with serum, followed by propidium iodide staining,
comparison of the PI (red, Fig. 3a) and FITC-a-CD20 (green,
Fig. 3b) channels revealed a number of cells that were recognized
by the antibody, but nonetheless remained alive during the 4 h
incubation period. This variation demonstrates the ability of this
assay platform to identify individual response behaviors even
within a single population of cultured cells. It is widely appreciated
that much greater cell-to-cell variation is present in primary tumor
tissue, and thus this method should be invaluable to groups
investigating the molecular basis of drug resistance.
Testing Antibody Specificity using Live Cell Arrays
An important consideration for the development of any
therapeutic antibody is the level of cytotoxicity specificity it can
achieve for its cellular target. This can easily be determined using
the same assay platform with fluorescence imaging at multiple
wavelengths. For example, a population of Jeko-1 (a CD20-postive
cell line) cells was labeled with Cell Tracker green and combined
with a population of Jurkat T-leukemia cells (a CD20-negative cell
line) that was labeled with Cell Tracker blue. The mixture of cells
was then bound to an array of 40 mm DNA capture spots, Fig. 4.
The CDC protocol described above was used, and the dead cells
were then stained with PI. There was a clear overlap between the
green (targeted) cells and the red PI stain (represented by yellow in
the merged image). In contrast, the blue Jurkat cells showed little
overlap with the PI stain, indicating the high degree of specificity
of the a-CD20 antibody for the CD20 receptor that only the Jeko-
1 cells possess. If desired, similar experimental configurations
could be designed to verify the specificity of antibody binding by
Measuring Cytotoxicity with Single Cell Resolution
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e66739
first labeling the immunoglobulin candidates with fluorescent dyes,
as described above.
ADCC Assays using Live Cell Arrays
A second and highly important mechanism of cytotoxicity
involves the recognition of antibody Fc regions by natural killer
cells. This antibody-dependent cellular cytotoxicity process is
particularly difficult to carry out on a single cell basis because it is
difficult to distinguish the targeted cells from effector cells supplied
as mixtures of peripheral blood mononuclear cells (PBMCs). By
binding only the targeted cells to the analysis surface, in addition
to labeling them with cytoplasmic dyes, the DNA-based cell array
method can lead to more accurate determinations of this process
than were previously possible. Triplicate samples of fluorescently
labeled Jeko-1 cells (blue) were arrayed in chamber slides and then
exposed to the a-CD20 antibody in varying concentrations for
30 min. Suspensions of PBMCs (AllCells, Inc., 25:1 E/T ratio)
were then added directly to the samples and incubated at 37uC for
16 h. Following the addition of the PI stain, fluorescence imaging
again revealed the ratio of dead to living cells, Fig. 5a–d.
Quantitation of the resulting samples again revealed a dose-
dependent response (Fig. 5e), with excellent plate-to-plate
reproducibility (,7% variation). Nearly 100% cytotoxicity was
observed at the highest a-CD20 concentration (100 mg/mL). Low
levels of killing, ranging between 5% and 10%, were detected after
Jeko-1 cells were incubated with a negative control antibody (NC
Ab) acquired from Eureka Therapeutics, Inc. The observed
ADCC EC50 value for a-CD20 compared well to the previously
published values of 0.02–0.5 mg/mL for Rituxan [18–21]. These
results highlight the value of being able to identify both the living
and the dead target cells in a complex mixture to obtain accurate
toxicity statistics. This is difficult to do using other methods. It is
also possible to conduct the same assay for resistant cells in the
context of an ADCC experiment when fluorescent antibodies are
used, as described above for CDC assays. Similar results were
obtained when primary B-chronic lymphoblastic leukemia cells
were used instead of Jeko-1 cells, Fig. 5f.
Cytotoxicity Assays Conducted in Whole Blood
While the ability to conduct CDC and ADCC assays
independently is important for determining the mechanism of
cytotoxicity, it would also be highly advantageous to evaluate the
efficacy of a therapeutic antibody candidate using whole blood
samples. This would effectively combine complement and cellular
toxicity activity, and would provide the most relevant information
regarding the specific response that a given patient would have.
Figure 1. Programing cellular adhesion using DNA hybridization. (a) The exposure of live cells to an activated DNA reagent results in the
rapid attachment of single strands to proteins in the cytoplasmic membrane. (b) Cell-substrate adhesion occurs within 5–20 min upon contact with a
surface that displays the complementary DNA sequence. (c) The result of this process is shown for a human T-cell cancer line (Jurkat) bound to a
5 mm DNA spot printed on a glass slide. Unbound cells were readily washed from the slide. (d) When combined with DNA patterns generated using
photolithography, ordered rectilinear arrays of cell clusters can also be produced. Both patterns are available in glass-bottomed chamber slides or 96-
well plates.
doi:10.1371/journal.pone.0066739.g001
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When combined with the ability of the cellular toxicity array
method to provide accurate data using very small cell samples, this
could lead to the personalized screening of antibody-based
therapies against the cells obtained from a single patient. Currently
Figure 2. Cell-array CDC assays. (a) Microarrays of treated Jeko-1 cells were stained using a solution of propidium iodide (PI) after 4 h. The dead
cells were imaged using a fluorescence microscope and counted using Image-J software, or quantified using an ImageXpress Micro automatic
imager. The merged bright field and PI images facilitated the unambiguous identification of the dead cells (see close-up image in Figure 3a). The
images labeled ‘‘NC Ab’’ correspond to a control antibody that did not bind the targeted cells. The scale bar in each image represents 100 mm. (b) A
dose-dependent response was observed for an anti-CD20 antibody (a-CD20). The error bars represent the standard deviation of three replicate
experiments. (c) Using time-lapsed imaging, the number of dead cells can be determined as a function of time. In this representation, 100%
represents the total number of dead cells observed at 4 h, which corresponds to 60% of the total cell population (as indicated on the plot in b). These
data correspond to the video that is available as supporting information.
doi:10.1371/journal.pone.0066739.g002
Figure 3. Images from a CDC assay using FITC-labeled a-CD20 at 10 mg/mL. Arrayed target cells (Jeko-1) were incubated with the antibody
in human serum for 4 h, and then stained with PI. (a) A merge of the bright field and red-fluorescence (PI) images clearly indicated the dead cells. (b)
The green fluorescence channel indicated that all of the target cells were bound by a-CD20. Comparison of the two images indicated which cells
resisted the CDC mechanism. The scale bar in each image represents 50 mm.
doi:10.1371/journal.pone.0066739.g003
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the only feasible way to evaluate cytotoxicity in whole blood is the
use of flow cytometry [27], which suffers from low sample
throughput and requires significantly larger numbers of cells.
To demonstrate this process, we first prepared a series of wells
containing fluorescently labeled target cells. Large DNA capture
spots were used in these assays, which removed one of the washing
steps from the procedure because all of the DNA-labeled cells were
bound by the plate surface. Triplicate samples (10,000 cells each)
were prepared in a 96-well plate, along with 500 nM PI stain. a-
CD20 was then added in varying concentrations. To each well
were added 180 mL of freshly drawn human blood (AllCells, Inc.).
After 16 h of incubation at 37uC, the samples were visualized
directly. Because the target cells are all immobilized in the same
focal plane, their fluorescence could be measured directly even
without removing the blood cells in the suspension above. As
shown in Fig. 6a–c, clear detection of the targeted cells (both alive
and dead) was possible. A dose-dependent response was again
observed, with only 5–7% well-to-well variance. An EC50 value of
0.3 mg/mL was obtained (Fig. 6d), which was in line with that
obtained in the CDC and ADCC assays. Thus, accurate data
could be obtained without the use of PBMCs, which are typically
only available in limited quantities. While CDC and ADCC assays
will likely remain the principal means of evaluating new antibody
candidates, this new whole blood assay can, in parallel, provide
information on the performance of the agents in a more realistic
sample matrix.
Conclusion
There are number of significant advantages of this new
cytotoxicity assay platform, including the use of smaller sample
sizes, the immobilization of the cells through stronger linkages to
minimize cell losses during the rinsing steps, the ability to obtain
real-time data, and the ability to capture specific live cells that
resist a given treatment method. Unlike most cytotoxicity assays,
which indirectly relate cell death to the release of cytoplasmic
contents into a bulk solution, this technique allows the researcher
to obtain more accurate cytotoxicity data by directly reporting the
number of living and dead cells. Such single-cell analysis
capabilities [28,29] were critically important to achieving the
high precision observed in these assays, enabled the use of much
smaller cell samples, and were required for the analysis of
cytotoxicity in whole blood. This is particularly powerful when
combined with the automated imaging and data analysis platforms
that are available from a number of different vendors. The 96-well
plate format allows replicate samples to be compared under
uniform experimental conditions, as evidenced by the low
variability between the wells in these experiments. Finally, the
compatibility of the DNA-based adhesion strategy with both
adherent and non-adherent cells allows these platforms to be
extended for use in many different types of drug screens.
High-throughput cytotoxicity assays, such as these, could help to
usher in a new era of personalized medicine. The small sample
Figure 4. Heterotypic cellular microarrays for the determination of CDC specificity. Cell Tracker-stained Jurkat (blue channel, bottom left)
and Jeko-1 (green channel, top right) cells were co-immobilized on cell microarrays. Following a CDC assay using 10 mg/mL a-CD20, the dead cells
were stained red with PI (upper left). The Jeko-1 fluorescence overlapped significantly with the PI stain (yellow cells, bottom right), showing the
degree of specificity of a-CD20 for CD20+ lymphoma cells. Overall, 76% of the Jeko-1 cells and 4% of the Jurkat cells were killed. The scale bar in each
image represents 50 mm.
doi:10.1371/journal.pone.0066739.g004
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sizes and rapid analyses associated with this platform allow many
more combinations of cell lines and drug candidates to be
evaluated than were previously possible. This can facilitate the
evaluation of combination therapies, in which two or more
antibodies that target complementary receptor groups are used in
concert. As each well requires 10,000 target cells or fewer, patient
biopsies and primary leukemia cells isolated from blood samples
can provide many more data points. This individualized screening
process becomes particularly powerful when combined with the
ability to evaluate the efficacy of a given agent in a patient’s own
blood, likely allowing a more accurate prediction of how a
therapeutic agent will perform once administered.
Materials and Methods
Preparation of Cell Microarrays
Cytolink cell microarray products were obtained from Adheren,
Inc., in either 8-well chamber slide or 96-well microtiter plate
formats. The cell microarrays were prepared following the
protocol provided by the manufacturer. In brief, 60 mL of a
0.39 mM solution of DNA with a thiol at the 59 end was reacted
with 0.2 mg of succinimidyl-[(N- maleimidopropionamido)-hex-
aethyleneglycol] (NHS-PEO6-maleimide) (Pierce) in 40 mL of
DMSO to obtain 1 mL of a 23.4 mM NHS-DNA solution in PBS
(pH 7.2). The target cells, which had been rinsed twice with PBS
before use, were then incubated with the NHS-DNA solution for
30 min at RT. Cell Tracker Blue or Green (Invitrogen, final
concentration of 500 nM) was added along with the NHS-DNA
Figure 5. Cell-array ADCC assays. The scale bar in each image represents 100 mm. (a) The bright field images show a mixture of indistinguishable
targeted cells and effector cells (PBMCs) after 16 h. (b) The Jeko-1 target cells were prestained with a Cell Tracker dye, allowing their facile detection
using fluorescence microscopy. (c) The dead cells were stained red using PI and counted using Image-J software or manually. (d) A merged image
allows the ratio of living (blue) to dead (purple) targeted cells to be determined. Red cells with no overlapping blue stain indicated dead effector cells,
which were not counted. Cellular microarray ADCC results are shown for the dose-dependent killing of (e) Jeko-1 cells and (f) primary B-chronic
lymphobatic leukemia cells with a-CD20 after 16 h. The error bars indicate the standard deviation of three replicate experiments.
doi:10.1371/journal.pone.0066739.g005
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solution if fluorescent labeling was needed. Following this, the cells
were washed twice with PBS containing 1% FBS, and resuspended
in a fresh portion of 1% FBS in PBS. In the case of 8-well chamber
slides, a suspension of 16107 cells/mL was prepared, and 100 mL
were added to each well. After 20 min of incubation at RT, the
samples in either format were washed twice with PBS/1% FBS to
remove any unbound cells. The cell microarrays were fully formed
at this point, and could be observed and counted by microscopy or
by using an automated imager.
For experiments that did not require the use of cell microarrays,
50 mL aliquots of the DNA-modified cells (56105 cells/mL) were
added to each DNA complement-coated well. After 20 min of
incubation at RT, all of the cells were bound to the surface. No
further rinses were required before the addition of antibody
solutions.
Antibodies
The antibodies used in the CDC and ADCC assays were
humanized anti-CD20 IgG1 (referred to as ‘‘a-CD20’’) and
ET901, which was raised against a proprietary non-mammalian
target (used as a control, listed as ‘‘NC Ab’’). Both were produced
in CHO cells and obtained from Eureka Therapeutics as solutions
in PBS and then diluted with PBS to generate a 2 mg/mL stock
solution. Portions of this solution were further diluted as required
before addition to the sample wells.
For experiments requiring fluorescent antibodies, the immuno-
globulins were labeled with fluorescein isothiocyanate (FITC) and
purified using gel filtration (NAP5 column, GE Healthcare) before
use.
Target Cell Preparation
The lymphoma cell line Jeko-1 was chosen for the ADCC and
CDC experiments, and Jurkat leukemia T-cells (which are CD20
negative) were chosen as a control cell line. Whole blood
cytotoxicity assays used Raji lymphoma cells. All cell lines were
obtained from the ATCC and maintained in RPMI 1640 culture
medium, supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 4 mM L-glutamine, and 500 IU/mL penicillin/
streptomycin (Life technologies) at 37uC in a 5% CO2 incubator.
Harvested cells were labeled with Cell Tracker Green or Cell
Tracker Blue in accordance with the manufacturer’s instructions.
The target cells were then immobilized on Cytolink cell
microrarray chamber slides or in 96-well plates, as described
above.
CDC Assays
Jeko-1 lymphoma cells were immobilized on Cytolink cell
microarrays in 8-well chamber slides. The assay buffer consisted of
RPMI +0.1% BSA +20 mM HEPES. The antibody was dissolved
in the assay buffer to form a series of stock solutions at twice the
desired final concentrations (which resulted in 0.01 to 100 mg/mL
concentrations after dilution in the sample wells). After the Jeko-1
cells had been bound by the microarray and the free cells had been
removed by rinsing, 200 mL of the antibody solution was added to
each well of the chamber slide. The resulting samples were
incubated on ice for 60 min. After this time, 200 mL of prepared
30% (v/v) human serum solution in assay buffer was added to each
chamber of the slide. Each sample was then incubated at 37uC
with 5% CO2 for 4 h. Cell viability was analyzed using a
propidium iodide (PI) solution (final concentration of 500 nM in
each well), and imaged using a fluorescence microscope or an
ImageXpress Micro (IXM) automated imager. The PI solution
was added at the end of the experiments, or it was added with the
serum if real-time images were to be collected.
Antibody Resistance Assays
Jeko-1 lymphoma cells were immobilized on Cytolink cell
microarrays in 8-well chamber slides. The assay buffer consisted of
RPMI +0.1% BSA +20 mM HEPES. The FITC labeled a-CD20
antibody was dissolved in the assay buffer to form a stock solution
at twice the desired final concentration (which resulted in 100 mg/
mL after dilution in the sample wells). After the Jeko-1 cells had
been bound by the microarray and the free cells had been
removed by rinsing, 200 mL of the antibody solution was added to
each well of the chamber slide. The resulting samples were
incubated on ice for 60 min. After this time, 200 mL of prepared
30% (v/v) human serum solution in assay buffer was added to each
chamber of the slide. Each sample was then incubated at 37uC
with 5% CO2 for 4 h. Cell viability was analyzed using a
propidium iodide (PI) solution (final concentration of 500 nM in
each well), and imaged using a fluorescence microscope or an
ImageXpress Micro (IXM) automated imager.
Effector Cell Preparation
The effector cells that were used were fresh PBMCs obtained
from AllCells, Inc. The effector cells were resuspended in RPMI
1640 culture medium, supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 4 mM L-glutamine, and 500 IU/mL
penicillin/streptomycin. Cell viability was determined by 0.4%
trypan blue exclusion before use.
ADCC Assays
Jeko-1 lymphoma cells were immobilized on Adheren Cytolink
cell microarrays in 8-well chamber slides. Before use, the Jeko-1
cells were stained fluorescent green using Cell Tracker Green. The
assay buffer consisted of RPMI +10% FBS +1% penicillin/
streptomycin. The antibody was dissolved in the assay buffer to
form a series of solutions at twice the intended final concentrations
(which resulted in 0.01 to 100 mg/mL concentrations after dilution
in the sample wells). After the cells had bound the microarray
surface and any free cells had been removed via rinsing, 200 uL of
antibody solution was added to each of the wells. The number of
Jeko-1 cells in each well was then counted using the IXM
automated imager or a fluorescence microscope. The samples
were next incubated at 37uC for 20 min. Fresh human PBMCs in
assay buffer were prepared at a concentration of 16106 cells/mL.
The desired volume of PBMCs was added to the wells to create a
ratio of 25:1 PBMCs to Jeko cells (E/T ratio = 25:1). The chamber
slide was then incubated at 37uC with 5% CO2 for 16 h. The
samples were washed gently three times to remove most of the
unbound effector cells, although this step was not necessary in all
cases. Cell viability was analyzed using PI staining (500 nM final
Figure 6. Antibody-based cytotoxicity measured in whole blood. The scale bar in each image represents 100 mm. (a) Raji lymphoma cells
were labeled with a blue Cell Tracker dye and then immobilized. Varying concentrations of a-CD20 were added, followed by freshly drawn human
blood. The targeted cells could be easily identified using fluorescence microscopy, even in the presence of a large excess of blood cells. (b) After 16 h,
the amount of cell death could be quantified using a PI stain (red). (c) A merged image allowed the ratio of living (blue) to dead (purple) targeted cells
to be determined. (d) The level of whole blood cytotoxicity is shown for a-CD20, in addition to a control antibody (red point). The error bars indicate
the standard deviation of two replicate experiments.
doi:10.1371/journal.pone.0066739.g006
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concentration), followed by cell counting with a microscopy
imager (IXM) or a fluorescence microscope.
Whole Blood Cytotoxicity Assays
Raji lymphoma cells were immobilized on Adheren Cytolink
96-well plates. In these experiments, the microarray cell patterns
were not used. The target cells were stained fluorescent green
before use with Cell Tracker Green. The assay buffer consisted of
RPMI +10% FBS +1% penicillin/streptomycin (Life technolo-
gies). The antibody was dissolved in assay buffer to form a series of
solutions at ten times the intended final concentrations (which
resulted in 0.025 to 100 mg/mL concentrations after dilution in
the sample wells). After the cells had bound the DNA-coated well
plates (no rinsing was required), 20 mL of antibody solution was
added to each of the sample wells. The plate was then incubated at
37uC for 20 min. A sample of heparinized fresh human whole
blood was obtained from Allcells, Inc. To each sample well was
added 180 uL of whole blood, and the resulting plate was then
incubated at 37uC with 5% CO2 for 16 h. After this time, cell
viability was analyzed directly (without rinsing away the effector
cells) using a PI stain (500 nM final concentration). The cells were
then imaged using a microscopy imager (IXM) or a fluorescence
microscope.
Supporting Information
Video S1 Time-lapsed images of the CDC process. Cell death
was monitored for 4 hours using the dose of a-CD20 (10 mg/mL).
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